title: The prevalence of prophylaxis for deep vein thrombosis in acute hospital trusts.
abstract: OBJECTIVE
  The effectiveness of activities to promote routine prophylaxis to prevent thromboembolism is difficult to assess because information about the prevalence of prophylaxis is sparse. The aim of this study was to assess the prevalence of deep vein thrombosis (DVT) prophylaxis for patients at risk in general medicine, general surgery, orthopaedics and gynaecology in Scotland and the North of England.
  
  
  METHODS
  Retrospective case note review of a random sample of episodes of care in a stratified random sample of directorates in Scotland and a convenience sample in England.
  
  
  METHODS
  Twenty acute hospital directorates in Scotland and eight in the North of England.
  
  
  METHODS
  Case notes of patients at risk of thrombosis and discharged from the selected directorates in a 12-month period (n = 742).
  
  
  METHODS
  The proportion of patients receiving prophylaxis in each directorate.
  
  
  RESULTS
  Overall, 469/526 (89%) of patients in Scotland and 199/216 (92%) in England received prophylaxis. The proportion varied from 71% in general medicine to 100% in orthopaedics. The frequency of use of different forms of prophylaxis varied between directorates. Approximately 60% of the patients who received prophylaxis received more than one form.
  
  
  CONCLUSIONS
  Prophylaxis for DVT is well established for procedures and conditions that are known to increase the risk of thrombosis and for which there are no contraindications. Additional efforts to promote prophylaxis for these conditions are unlikely to be cost effective. Further research is needed to establish whether rates are equally high in other conditions, and whether the high prophylaxis rates are due to clinical effectiveness initiatives.
authors.affiliation: Health Services Research Unit, University of Aberdeen, UK.
authors.forename: S E
authors.initials: SE
authors.lastname: Campbell
authors.forename: A E
authors.initials: AE
authors.lastname: Walke
authors.forename: J M
authors.initials: JM
authors.lastname: Grimshaw
authors.forename: M K
authors.initials: MK
authors.lastname: Campbell
authors.forename: G D
authors.initials: GD
authors.lastname: Lowe
authors.forename: D
authors.initials: D
authors.lastname: Harper
authors.forename: F G
authors.initials: FG
authors.lastname: Fowkes
authors.forename: J C
authors.initials: JC
authors.lastname: Petrie
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000075202:Contraindications; D004739:England; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006779:Hospitals, Public / Q000592:standards*; D006801:Humans; D017410:Practice Guidelines as Topic; D011292:Premedication / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D012606:Scotland; D013222:State Medicine / Q000592:standards; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight